Abstract: The present invention aims to provide a method for removing glycosylation isomers in antibody drugs, etc. The present invention provides, for example, a purification method for an antibody composition, said method comprising: loading the antibody composition on conventional chromatography to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to a media of the chromatography; and treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition.

Abstract: The present invention provides a therapeutic agent and a therapeutic method for cancer, etc., capable of exerting a more potent and sustained antitumor effect than existing FGFR4-selective tyrosine kinase inhibitors. The present invention is directed to a pharmaceutical combination for the treatment of cancer, characterized by comprising: a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof; and an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.

Abstract: The present invention is intended to provide: an anti-hCDCP1 antibody, which can be used as an active ingredient of anticancer agents having few side effects, etc.; and the aforementioned anti-hCDCP1 antibody that is formulated into ADC. Specifically, the present invention relates to an antibody that binds to human CDCP1 (CUB domain-containing protein 1), which has low binding property to human CD34-positive cells, or an antigen-binding fragment thereof.

Abstract: The present invention relates to a method for promoting diversification of variable regions of an antibody. Specifically, the present invention relates to a method for promoting diversification of the amino acid sequences of variable regions of an antibody generated by an avian B cell population, wherein the method comprises suppressing the PI3K? activity of each avian B cell comprised in the avian B cell population expressing the antibody.

Abstract: The present invention provides a therapeutic agent and a therapeutic method for hepatocellular carcinoma, etc., capable of exerting a more potent and sustained antitumor effect than existing multikinase inhibitors. The present invention is directed to a pharmaceutical combination for treating hepatocellular carcinoma, which is characterized by comprising lenvatinib or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof, and an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.

Abstract: The present invention relates to a method for obtaining an antibody from an avian B cell antibody library, comprising the following steps (a) to (d): (a) a step of allowing an avian B cell antibody library to come into contact with an antigen in the presence of a calcineurin inhibitor and avian serum, (b) a step of selecting avian B cells that bind to the antigen in the step (a), (c) a step of culturing the avian B cells selected in the step (b) in the presence of a calcineurin inhibitor and avian serum, and (d) a step of obtaining the avian B cells obtained through the step (c) and/or an antibody expressed by the avian B cells.

Abstract: The present invention relates to a bispecific binding molecule comprising three binding domains, wherein a first and/or a second binding domain are capable of binding to the extracellular 5T4 antigen and the remaining binding domain(s) is (are) capable of binding to the CD3 receptor complex on T cells. Moreover, the invention relates to a nucleic acid sequence encoding fusion protein, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates to a process for the production of the fusion protein of the invention, a medical use of said fusion protein and a kit comprising said fusion protein.

Abstract: The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.

Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Abstract: The present invention provides: an antibody, which specifically reacts with hTROP-2 and has anti-tumor activity in vivo; a hybridoma, which produces the aforementioned antibody; a complex of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.

Abstract: The present invention provides a method for obtaining diverse novel genes by inducing somatic cell homologous recombination at genetic loci in somatic cells. By controlling transcription activity of a gene that exists at a genetic locus in a eukaryotic organism cell wherein DNA homologous recombination is occurring at an arbitrary genetic locus, somatic cell homologous recombination is induced between said gene and a gene having a DNA sequence similar to said gene that exists in a region upstream of a transcription promoter, whereby it is possible to obtain diverse novel genes having a plurality of genetic information.

Abstract: The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.

Abstract: Disclosed is a method for producing an antibody directed against a protein, particularly a transmembrane protein, expressed on the surfaces of cells. Specifically disclosed is a means for obtaining a desired antibody by mixing cells capable of expressing an antigen protein on the surfaces thereof (i.e., antigen molecule-expressing cells) with an antibody library composed of antibody-expressing cells, viruses or the like, and subsequently concentrating/isolating only components (e.g., antibody-expressing cells, viruses) capable of binding to the antigen molecule-expressing cells from the components (e.g., antibody-expressing cells, viruses) of the antibody library.

Abstract: The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible. The production of antibodies that bind specifically to antigens from cell populations in which the antibody molecules have been diversified by the enhancement of somatic homologous recombination is made possible by using an appropriate selection method (for example, beads coated with antigen and the like).

Abstract: Disclosed is a method for producing an antibody directed against a protein, particularly a transmembrane protein, expressed on the surfaces of cells. Specifically disclosed is a means for obtaining a desired antibody by mixing cells capable of expressing an antigen protein on the surfaces thereof (i.e., antigen molecule-expressing cells) with an antibody library composed of antibody-expressing cells, viruses or the like, and subsequently concentrating/isolating only components (e.g., antibody-expressing cells, viruses) capable of binding to the antigen molecule-expressing cells from the components (e.g., antibody-expressing cells, viruses) of the antibody library.